Search

Displaying results 7781 - 7790 of 8468 in total
  1. Drug

    Afimetoran

    go.drugbank.com/drugs/DB16580
    Investigational

    Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioac...

  2. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  3. Drug

    Flurocitabine

    go.drugbank.com/drugs/DB20317
    Experimental

    Flurocitabine has a monoisotopic molecular weight of 243.07 Da.

  4. Drug

    Navamepent

    go.drugbank.com/drugs/DB21096
    Investigational

    Navamepent has a monoisotopic molecular weight of 304.17 Da.

  5. Drug

    Aderbasib

    go.drugbank.com/drugs/DB21288
    Investigational

    Aderbasib has a monoisotopic molecular weight of 416.21 Da.

  6. Drug

    Acloproxalap

    go.drugbank.com/drugs/DB21553
    Investigational

    Acloproxalap has a monoisotopic molecular weight of 202.11 Da.

  7. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    Thus, as of July 2020, BBV152 is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519). … The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel)

  8. Drug

    NC-6300

    go.drugbank.com/drugs/DB17341
    Experimental

    NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

  9. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination

  10. Drug

    Teprenone

    go.drugbank.com/drugs/DB15955
    Investigational